eplivanserin
Small moleculeexperimental
Eplivanserin was an experimental drug for the treatment of insomnia which was being developed by Sanofi Aventis. — Wikipedia
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
5
Phase 4
0
Earliest trial started Apr 1, 2004 (NCT00313885)
Timeline
Indications
Mechanism of action
- Serotonin 2a (5-HT2a) receptorANTAGONIST
HTR2A antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)CCO/N=C(/C=C/c1ccc(O)cc1)c1ccccc1F- Mol. weight
- 328.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEplivanserin ↗
- ChEMBLCHEMBL257704 ↗
Also known as
- 2-propen-1-one, 1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-, o-(2-(dimethylamino)ethyl)oxime, (z,e)-, (e)-2-butenedioate (2:1) (salt)
- 4-((3z)-3-(2-dimethylaminoethyl)oxyimino-3-(2-fluorophenyl)propen-1-yl)phenol hemifumarate
- eplivanserin
- eplivanserin
- eplivanserin
- eplivanserin
- sr 46349
- sr-46349
- sr-46349
- sr-46349
- sr 46349b
- sr-46349b
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00913614 | Phase 1 | Jun 1, 2009 | Sanofi |
| NCT00805350 | Phase 3 | Dec 1, 2008 | Sanofi |
| NCT00679900 | Phase 3 | Apr 1, 2008 | Sanofi |
| NCT00308503 | Phase 3 | Feb 1, 2006 | Sanofi |
| NCT00253968 | Phase 3 | Nov 1, 2005 | Sanofi |
| NCT00253903 | Phase 3 | Nov 1, 2005 | Sanofi |
| NCT00313885 | Phase 2 | Apr 1, 2004 | Sanofi |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 7 | 7 | 3 | 2004 |
1 organizations
Page 1 / 1